Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms
, , , , , y
07 jul 2022
Acerca de este artículo
Categoría del artículo: Original article
Publicado en línea: 07 jul 2022
Páginas: 126 - 130
Recibido: 01 feb 2022
Aceptado: 01 may 2022
DOI: https://doi.org/10.2478/aiht-2022-73-3635
Palabras clave
© 2022 Snežana Đorđević, Nataša Perković Vukčević, Marko Antunović, Vesna Kilibarda, Gordana Vuković Ercegović, Jasmina Jović Stošić, and Slavica Vučinić, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Patients with serum olanzapine concentrations above the lethal threshold of 1 mg/L
| Patient | Sex | Age | Ingested dose | Time from ingestion to blood collection | Concentration (mg/L) | PSS |
|---|---|---|---|---|---|---|
| 1 | male | 26 | about 150 mg | 6 h | 3.40 | 2 |
| 2 | female | 26 | 1680 mg | 5 h | 2.44 | 3 |
| unknown | >12 h | 1.75 | 3 | |||
| 3 | female | 59 | 560 mg | 3 h | 1.53* | 4 |
| 4 | male | 43 | unknown | >24 h | 1.18 | 3 |
Serum concentrations of co-ingested drugs (mg/L) during the hospitalisation
| Day | Olanzapine (mg/L) | Clozapine (mg/L) | Norclozapine (mg/L) | Lamotrigine (mg/L) | Midazolam (mg/L) | Zolpidem (mg/L) |
|---|---|---|---|---|---|---|
| 1 | 0.28 | 0.29 | 0.02 | 3.62 | 0.21 | 0.83 |
| 2 | 0.42 | 0.22 | 0.03 | 2.19 | <LOD | 0.19 |
| 3 | 0.59 | 0.49 | <LOD | 2.74 | <LOD | 0.15 |
| 4 | 1.53 | 0.68 | <LOD | 3.5 | <LOD | 0.14 |
| 5 | 0.31 | 0.7 | <LOD | < 1.0 | <LOD | 0.06 |